Thursday, November 18, 2010
Prof Timothy Perren - Leeds Teaching Hospitals NHS Trust, UK, The ICON7 trial on ecancer tv (Avastin)
Wednesday, November 17, 2010
".....The team, testing 203 samples with OncoMap, found mutations of 50 genes in total. Some mutations were in genes previously identified in ovarian cancer, including KRAS, CTNNB1, and PIK3CA. Others were not previously known to occur in this disease, but, importantly, are potential drug targets with existing agents. "It’s not like HER2 in breast cancer where that is found in about 30% of breast cancers – we found many mutations in the ovarian cancer samples and they were infrequent," Dr. Matulonis said in a telephone interview prior to the conference; she noted, however, that OncoMap identified KRAS and PIK3CA mutations as the most common, occurring in about 25% of tumors, and "that was reassuring," as it was in line with expectations..........Dr. Matulonis’ team is now using OncoMap on all new ovarian cancers, including nonserous cancers, diagnosed at Dana-Farber, and she predicted the test will become standard in clinical practice within 6 months to a year..........cont'd
(Halifax, NS) Immunovaccine Inc. Announces Phase I/II Clinical Plan for DPX-Survivac to Target Ovarian Cancer - MarketWatch
PARP (1 and 2) inhibitor, MK-4827, shows anti-tumor activity in first trial in humans (mutation/non mutation carriers)
"He gave a possible explanation as to why patients with cancers that were not caused by BRCA1/2 mutations also responded to the PARP inhibition. "BRCA is a tumour suppressor gene that assists in repairing double stranded DNA breaks. In BRCA-mutation related cancers, loss of both copies of the gene results in a non-functional protein and thus BRCA deficiency. Because BRCA works with other proteins, BRCA-pathway related deficiency can be seen in the absence of two mutated copies of the BRCA genes. This may explain why responses have been reported for this class of drugs in non-BRCA mutant cancers."
science article: Duke continues investigation as geneticist's work retracted (ovarian cancer patients to cisplatin drug therapy)
A prIME Oncology educational activity held after the official ESMO program hours: Evolving Strategies in the Management of Advanced Ovarian Cancer Oct
Defining the rationale and role for targeted therapy in ovarian cancer
Nicoletta Colombo, MD
Targeting angiogenesis: Where are we in 2010?
Robert A. Burger, MD, FACOG, FACS
Beyond antiangiogenesis: What are the options?
Andres Poveda, MD
This Webcast contains video and downloadable slides from our symposium “Evolving Strategies in the Management of Advanced Ovarian Cancer,” a prIME Oncology educational activity that was held after the official ESMO program hours on Monday, 11 October in Milan, Italy.
Tuesday, November 16, 2010
Nov 16th: Wide Genetic Testing for Lynch Syndrome Cost Effective « AACR News telephone conference Nov 18th ET U.S./Canada
The American Association for Cancer Research will host a teleconference on these findings on Thursday, Nov. 18, 2010, at 3:00 p.m. ET. Reporters and other interested parties can participate by using the following information:
- Dial-in (U.S. and Canada): (888) 282-7404
- Dial-in (International): (706) 679-5207
- Access Code: 20084557
Updated Oct 2010: Genetic Syndromes - Genetics of Breast and Ovarian Cancer - National Cancer Institute
Penetrance of Mutations
Cancer risk in individuals who test negative for a known familial BRCA1/2 mutation
Breast and ovarian cancer risk in breast cancer families without detectable BRCA1/2 mutations
An archived video of the full meeting is available through the NIH Videocast Web site.
"...Li-Fraumeni syndrome was first described in a 1969 publication in the Annals of Internal Medicine by Dr. Joseph F. Fraumeni, Jr., the director of DCEG, and his colleague Dr. Frederick P. Li. They described four families in which several members developed a wide variety of cancers as children or young adults. Many of the patients had multiple primary tumors, most notably breast cancer, soft tissue and bone sarcomas, brain tumors, adrenocortical neoplasms, and acute leukemia. Subsequent studies identified additional families that met the classic criteria for LFS. Other families had similar but less pronounced aggregations of cancer and were classified as Li-Fraumeni-like (LFL)...."
Expansion of cancer care and control in countries of low and middle income: a call to action : The Lancet
Note: includes a number of easy to read charts/comparisons
abstract + Free Full-Text (2010) Familial Pancreatic Cancer (includes discussion regarding BRCA/Lynch Syndrome/FAMMM and others)
Abstract: Pancreatic cancer’s high mortality rate equates closely with its incidence, thereby showing the need for development of biomarkers of its increased risk and a better understanding of its genetics, so that high-risk patients can be better targeted for screening and early potential lifesaving diagnosis. Its phenotypic and genotypic heterogeneity is extensive and requires careful scrutiny of its pattern of cancer associations, such as malignant melanoma associated with pancreatic cancer, in the familial atypical multiple mole melanoma syndrome, due to the CDKN2A germline mutation. This review is designed to depict several of the hereditary pancreatic cancer syndromes with particular attention given to the clinical application of this knowledge into improved control of pancreatic cancer.
Keywords: phenotypic and genotypic heterogeneity; high mortality; genetic counseling; biomarker paucity; FAMMM syndrome; Li-Fraumeni syndrome; Lynch syndrome; pancreatic cancer
Monday, November 15, 2010
"Recent studies have also shown anti-tumour efficacy in several types of cancers but this is the first time it has been studied for the treatment of ovarian cancer."
Note: Medscape requires (free) registration to view
"Sadly, the political rancour about who spends what and on whom diverts attention from the real key to tackling chronic disease, and the only thing with the power to save both lives and money—disease prevention."
a collection of videos: Ovarian Cancer - Cancer Health (including Ovarian Cancer and Our Pets - minus audio)
Note: search blog for additional RAD51 information/studies
Margaret Polaneczky, MD - HRT Worries – This Time, It’s Ovarian Cancer Again…. | The Blog That Ate Manhattan (see simple charts)
Ovarian cancer drug shows promise with move to phase 3 trial (AMG 386) Clinical Oncological Society of Australia
Sunday, November 14, 2010
Surgical management of recurrent ovarian cancer: The advantage of collaborative surgical management and a multidisciplinary approach.
CONCLUSIONS: Previous studies document survival benefit of surgery for women with recurrent ovarian cancer when there has been a long disease-free interval, localized pelvic or intra-abdominal recurrences and an optimal performance status. Most gynecologic oncologists do not perform extensive liver or diaphragm resections or lymph node excision above the renal vessels; thus, collaboration with a surgical oncologist is a viable option. In this small descriptive study, the feasibility of this reasonably well-tolerated approach, with possible survival benefit, is documented.
Does the time interval between first and last birth influence the risk of endometrial and ovarian cancer?
CONCLUSION: Our findings suggest that the risk of endometrial cancer is significantly decreased for women having at least a difference of 10 years between their first and last birth. Ovarian cancer does not seem to be influenced by the time interval between first and last birth.
The impact of systematic para-aortic and pelvic lymphadenectomy on survival in patients with optimally debulked ovarian cancer
AbstractAIM: The objective of this study was to verify the impact of systematic retroperitoneal lymphadenectomy on survival in patients with ovarian cancer.
CONCLUSION: This study has demonstrated that the systematic lymphadenectomy had benefit only in patients with ovarian cancer macroscopically confined to the pelvis. In patients with clear cell adenocarcinoma, systematic lymphadenectomy was beneficial. To the contrary, systematic lymphadenectomy had no benefit on OS or PFS in patients with advanced ovarian cancer if optimally debulked.
The use of recombinant erythropoietin for the treatment of chemotherapy-induced anemia in patients with ovarian cancer does not effect progression-free or overal survival
AbstractBACKGROUND.: Studies have suggested that erythropoietin-stimulating agents (ESAs) may effect progression-free survival (PFS) and overall survival (OS) in a variety of cancer types.
Phase 1b-2a study to reverse platinum resistance through use of a hypomethylating agent, azacitidine, in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer
BACKGROUND: Sequential treatment with azacitidine can induce re-expression of epigenetically silenced genes through genomic DNA hypomethylation and reverse carboplatin resistance of epithelial ovarian cancer cells. A phase 1b-2a clinical trial of this sequential combination of azacitidine and carboplatin was initiated in patients with platinum-resistant or platinum-refractory epithelial ovarian cancer.
Endometroid adenocarcinoma of the uterus, borderline tumor of the ovary and Brenner tumor of the contralateral ovary (case report)
Definition: Brenner tumours are uncommon tumours that are part of the surface epithelial-stromal tumour group of ovarian neoplasms
Definition: Atherosclerosis (also known as arteriosclerotic vascular disease or ASVD) is the condition in which an artery wall thickens as the result of a build-up of fatty materials such as cholesterol
Consumption of dietary fat and meat and risk of ovarian cancer - the American Journal of Clinical Nutrition
Design: The NLCS includes 62,573 postmenopausal women, aged 55–69 y at baseline, who completed a baseline questionnaire on dietary habits and other risk factors for cancer in 1986. After 16.3 y of follow-up, 340 ovarian cancer cases and 2161 subcohort members were available for a case-cohort analysis. Multivariable rate ratios (RRs) were adjusted for age at baseline, total energy intake, oral contraceptive use, and parity
[18F]FDG-PET/CT monitoring early identifies advanced ovarian cancer patients who will benefit from prolonged neo-adjuvant chemotherapy.
AbstractAIM: The most accepted standard duration of neoadjuvant chemotherapy (na-CHT) before debulking surgery for advanced ovarian cancer (AOC) is 3 courses. However a percentage of patients could benefit from additional courses......
Clinical consequences of the Calypso trial showing superiority of PEG-liposomal doxorubicin and carboplatin over paclitaxel and carboplatin in recurrent ovarian cancer: Results of an Austrian gynecologic oncologists' expert meeting.
Opening the psychological black box in genetic counseling. The psychological impact of DNA testing is predicted by the counselees' perception, the medical impact by the pathogenic or uninformative BRCA1/2-result.
Book Review - The Emperor of All Maladies - A Biography of Cancer - By Siddhartha Mukherjee - NYTimes.com
Tuesday, October 19, 2010
Comments | Decisions at the end of life: have we come of age? full free access - open for commentary
Congratulations to the authors for addressing the issue of changing values and needs of patients at the close of life. Most North American studies on this topic err in their original suppositions regarding the preferred place of death. Generally the focus has been institutional and cost based as opposed to the values and ethics of yes, human dignity in dying. Specific to the needs of oncology patients/families, it is often disturbing to view reports asking citizens where they wish to die when we should know and understand that this answer cannot be of any value until those patients and families are 'in the moment'. The moment-to-moment changes in physical and emotional changes in cancer patients/families and all of the psycho-physio changes require that our systems adapt. Numerous real life examples of institutional/provider interference in the wishes of the dying are disturbingly unconscionable. The question which needs to be addressed is: 'Who's on 'first'?" Having witnessed circumstances where best practices were not followed in favour of cost analyses, we have to ask ourselves who will say no to money before suffering?
ovarian cancer survivor, Lynch Syndrome